TRCT
ZNTL icon

Tower Research Capital (TRC)’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Tower Research Capital (TRC)’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.65K Buy
+1,134
New +$2.93K ﹤0.01% 4441
2025
Q4 		– Sell
-29,386
Closed -$44.4K – 5680
2025
Q3 		$44.4K Buy
29,386
+12,272
+72% +$18.4K ﹤0.01% 2622
2025
Q2 		$19.9K Buy
17,114
+11,873
+227% +$15.7K ﹤0.01% 3686
2025
Q1 		$8.33K Sell
5,241
-3,394
-39% -$7.32K ﹤0.01% 3901
2024
Q4 		$26.2K Buy
8,635
+686
+9% +$2.25K ﹤0.01% 2980
2024
Q3 		$29.3K Sell
7,949
-29,536
-79% -$107K ﹤0.01% 3017
2024
Q2 		$153K Buy
37,485
+37,421
+58,470% +$418K ﹤0.01% 2269
2024
Q1 		$1.01K Sell
64
-3,551
-98% -$48.8K ﹤0.01% 5347
2023
Q4 		$54.8K Buy
3,615
+2,589
+252% +$37.8K ﹤0.01% 3069
2023
Q3 		$20.6K Sell
1,026
-5,894
-85% -$150K ﹤0.01% 3345
2023
Q2 		$195K Buy
6,920
+4,829
+231% +$116K 0.01% 1573
2023
Q1 		$36K Sell
2,091
-487
-19% -$9.86K ﹤0.01% 2821
2022
Q4 		$51K Sell
2,578
-3,443
-57% -$74K ﹤0.01% 2341
2022
Q3 		$130K Sell
6,021
-1,619
-21% -$44.3K ﹤0.01% 2326
2022
Q2 		$215K Buy
7,640
+7,122
+1,375% +$189K ﹤0.01% 1719
2022
Q1 		$24K Sell
518
-3,424
-87% -$185K ﹤0.01% 3381
2021
Q4 		$331K Buy
3,942
+1,325
+51% +$103K 0.01% 1409
2021
Q3 		$175K Sell
2,617
-467
-15% -$26.9K ﹤0.01% 1941
2021
Q2 		$164K Buy
3,084
+1,640
+114% +$87.8K ﹤0.01% 2072
2021
Q1 		$63K Buy
1,444
+726
+101% +$31.3K ﹤0.01% 2935
2020
Q4 		$37K Sell
718
-8,516
-92% -$384K ﹤0.01% 3404
2020
Q3 		$302K Buy
9,234
+8,724
+1,711% +$305K ﹤0.01% 2184
2020
Q2 		$24K Buy
+510
New +$19.6K ﹤0.01% 3594

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Tower Research Capital (TRC)'s ZNTL Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2026: 1,134 shares worth $2.65K. The stake represents ﹤0.01% of the portfolio and ranks #4441 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in ZNTL as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in ZNTL in Q2 2020 and has held it in 23 quarters since. The position peaked at $331K in Q4 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Tower Research Capital (TRC) held 1,134 shares of Zentalis Pharmaceuticals worth $2.65K as of Q1 2026.
  • Zentalis Pharmaceuticals was a new Tower Research Capital (TRC) position in Q1 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4441 holding.
  • Tower Research Capital (TRC) first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • Tower Research Capital (TRC)'s Zentalis Pharmaceuticals position peaked at $331K in Q4 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.